Immuno-modulating antitumor activities of Ganoderma lucidum (Reishi) polysaccharides

• US 7,560,114 B2
• Filed: 12/06/2007
• Issued: 07/14/2009
• Est. Priority Date: 08/06/2001
• Status: Active Grant

• Current Assignee: Chi-Huey Wong, Chun-Cheng Lin, Chun-Hung Lin, Hong-Sen Chen, Kay-Hooi Khoo, Shui-Tein Chen, Yow-Fu Tsai, Yuan-Yuan Wang
• Original Assignee: Chi-Huey Wong, Chun-Cheng Lin, Chun-Hung Lin, Hong-Sen Chen, Kay-Hooi Khoo, Shui-Tein Chen, Yow-Fu Tsai, Yuan-Yuan Wang
• Inventors: Lin, Chun-Cheng, Khoo, Kay-Hooi, Wang, Yuan-Yuan, Tsai, Yow-Fu, Chen, Hong-Sen, Chen, Shui-Tein, Lin, Chun-Hung, Wong, Chi-Huey
• Primary Examiner(s): Tate; Christopher R
• Assistant Examiner(s): WINSTON, RANDALL O
• Application Number:
  US11/952,032
• Publication Number:
  US 20080267991A1
• Time in Patent Office: 586 Days
• Field of Search: None
• US Class Current: 424/195.15
• CPC Class Codes: A23L 33/105 Plant extracts, their artificial duplicates or their derivatives
• CPC Class Codes: A61K 36/074 Ganoderma

Abstract

The present invention provides methods of modulating an immune response in an organism by administering medicinally active extracts and fractions, and a method for preparing the same by extracting and fractioning constituents from the tissue of components of Ganoderma lucidum.

Claims

1. A method for modulating an immune response in an organism in need thereof comprising administering to said organism an effective amount of a purified extract from Ganoderma lucidum comprising a polysaccharide or glycopeptide component having a terminal fucose residue with α

1,2-fucosidic linkages, wherein said purified extract is obtained by the method comprising;

homogenizing a tissue of Ganoderma lucidum;

extracting the homogenized tissue with aqueous alkaline solution to form a crude extract; and

subjecting the crude extract to gel filtration chromatography to form one or more fractions buffered at a pH of about 7, the one or more fractions comprising said polysaccharide or glycopeptides component having terminal fucose residues with α

1,2-fucosidic linkages;

wherein the purified extract comprises at least one of the fractions.

2. The method of claim 1 wherein the aqueous alkaline solution is NaOH solution.

3. The method of claim 1 wherein the NaOH solution is a 0.1 N solution.

4. The method of claim 1 wherein the gel filtration chromatography step is performed using a Sephracryl S-500 column.

7. The method of claim 1 wherein said organism is a human.

5. A method for modulating an immune response in an organism in need thereof comprising administering to said organism an effective amount of a purified extract from Ganoderma lucidum comprising a polysaccharide or glycopeptide component having a terminal fucose residue with α

1,2-fucosidic linkages, wherein said purified extract is obtained by the method comprising;

homogenizing a tissue of Ganoderma lucidum;

extracting the homogenized tissue with aqueous alkaline solution to form a crude extract;

subjecting the crude extract to gel filtration chromatography to form one or more fractions buffered at a pH of about 7; and

partitioning the one or more fractions with an anion exchanger to form one or more subfractions, the one or more subfractions comprising said polysaccharide or glycopeptide comprising terminal fucose residues with a 1,2-fucosidic linkages;

wherein the purified extract comprises at least one of the subfractions.

6. A method for modulating an immune response in an organism in need thereof comprising administering to said organism an effective amount of a purified extract from Ganoderma lucidum comprising a polysaccharide or glycopeptide component having a terminal fucose residue with α

1,2-fucosidic linkages, wherein said purified extract is obtained by the method comprising;

homogenizing a tissue of Ganoderma lucidum;

extracting the homogenized tissue with aqueous alkaline solution to form a crude extract;

subjecting the crude extract to gel filtration chromatography to form one or more fractions buffered at a pH of about 7;

partitioning the one or more fractions with an anion exchanger to form one or more subfractions; and

partitioning the one or more subfractions by gel filtration to form one or more partitioned subfractions, the one or more partitioned subfractions comprising said polysaccharide or glycopeptide comprising terminal fucose residues with α

1,2-fucosidic linkages;

wherein the purified extract comprises at least one of the partitioned subfractions.